Tanvex BioPharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	224.83	34.68	61.41	22.4	5.41	0.3
Revenue Growth (YoY)	448.96%	-43.53%	174.11%	314.43%	1702.00%	-
Cost of Revenue	420.38	26.39	1.71	41.75	1.86	0.16
Gross Profit	-195.55	8.29	59.7	-19.35	3.55	0.14
Selling, General & Admin	416.51	306.52	453.71	234.74	219.21	239.12
Research & Development	685.86	1,059	1,707	1,351	1,384	1,861
Operating Expenses	1,096	1,365	2,160	1,586	1,603	2,100
Operating Income	-1,292	-1,357	-2,101	-1,606	-1,599	-2,100
Interest Expense	-48.4	-53.34	-57.38	-54.72	-46.22	-18.57
Interest & Investment Income	35.63	30.18	29.04	9.6	3.14	18.66
Currency Exchange Gain (Loss)	-72.92	17.98	1.32	12.48	7.16	-5.63
Other Non Operating Income (Expenses)	-1.36	-19.17	1.88	4.25	92.85	1.18
EBT Excluding Unusual Items	-1,379	-1,381	-2,126	-1,634	-1,542	-2,104
Gain (Loss) on Sale of Assets	15.21	0.08	-2.87	-7.21	-0.94	-0.27
Asset Writedown	-49.19	-	-8.67	-	-	-
Other Unusual Items	52.21	-0.19	0.77	-	-	-
Pretax Income	-1,361	-1,381	-2,137	-1,641	-1,543	-2,104
Income Tax Expense	-3.02	0.35	0.43	0.02	0.02	0.02
Net Income	-1,358	-1,382	-2,137	-1,641	-1,543	-2,104
Net Income to Common	-1,358	-1,382	-2,137	-1,641	-1,543	-2,104
Shares Outstanding (Basic)	220	155	129	118	109	89
Shares Outstanding (Diluted)	220	155	129	118	109	89
Shares Change (YoY)	48.73%	20.44%	9.60%	8.31%	21.32%	9.25%
EPS (Basic)	-6.18	-8.90	-16.58	-13.95	-14.21	-23.51
EPS (Diluted)	-6.18	-8.90	-16.58	-13.95	-14.21	-23.51
Free Cash Flow	-1,355	-1,257	-1,506	-1,427	-1,417	-1,854
Free Cash Flow Per Share	-6.17	-8.09	-11.69	-12.14	-13.05	-20.71
Gross Margin	-86.98%	23.91%	97.21%	-86.36%	65.67%	47.67%
Operating Margin	-574.68%	-3912.40%	-3420.80%	-7166.21%	-29581.65%	-699859.00%
Profit Margin	-603.94%	-3983.94%	-3480.00%	-7325.16%	-28546.26%	-701412.00%
Free Cash Flow Margin	-602.79%	-3623.36%	-2452.94%	-6370.97%	-26208.75%	-617884.67%
EBITDA	-1,125	-1,253	-1,976	-1,492	-1,496	-1,958
D&A For EBITDA	166.99	103.76	124.89	113.22	102.84	141.87
EBIT	-1,292	-1,357	-2,101	-1,606	-1,599	-2,100

Source: S&P Global Market Intelligence. Standard template. Financial Sources.